Prostate Cancer - Results from #28200

Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer - Abstract April 21, 2011

Documenting the location of systematic transrectal ultrasound-guided prostate biopsies: Correlation with multi-parametric MRI - Abstract April 21, 2011

Impact of nocturia on disease-specific quality of life for men with localized prostate cancer - Abstract April 21, 2011

Side-effects of post-treatment biopsies in prostate cancer patients treated with endocrine therapy alone or combined with radical radiotherapy in the Scandinavian Prostate Cancer Group-7 randomized trial - Abstract April 21, 2011

Provenge: Revolutionary technology or ethical bust? - Abstract April 21, 2011

Androgen deprivation therapy in prostate cancer: Are rising concerns leading to falling use? - Abstract April 21, 2011

Editor's Commentary - Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement April 21, 2011

EAU 2011 - Prostate cancer screening: Can it be improved with total testosterone levels? - Session Highlights April 21, 2011

EAU 2011 - Prostate cancer incidence and disease-specific survival in men participating in the ERSPC with an initial PSA under 3.0 ng/ml - Session Highlights April 21, 2011

Association of black race with follow-up of an abnormal prostate-specific antigen test - Abstract April 20, 2011

Repeat prostate biopsies predict location of index cancer in an active surveillance cohort - Abstract April 20, 2011

Role for stromal heterogeneity in prostate tumorigenesis - Abstract April 20, 2011

Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide - Abstract April 20, 2011

Antitumor effects of carnertinib in castration resistant prostate cancer models: A Comparative study with erlotinib - Abstract April 20, 2011

The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer - Abstract April 20, 2011

No evidence of XMRV in prostate cancer cohorts in the Midwestern United States - Abstract April 20, 2011

Prostate cancer and ambient pesticide exposure in agriculturally intensive areas in California - Abstract April 20, 2011

PSA quo vadis? It is reasonable to start with prostate-specific antigen testing at the age of 40! - Abstract April 20, 2011

EAU 2011 - Oncological outcomes of high-intensity focused ultrasound for localized prostate cancer in 880 consecutive patients - Session Highlights April 20, 2011

EAU 2011 - Race and treatment choice affect cancer specific and overall survival differently in 16,508 men with localized prostate cancer treated in Cancer Research Networks in the United States - Session Highlights April 20, 2011

Page 1411 of 1436